CA240-0030: BMS-986504 in Untreated Metastatic Pancreatic Cancer with Homozygous MTAP Deletion

  • Research type

    Research Study

  • Full title

    A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion

  • IRAS ID

    1009226

  • Contact name

    Beth Osoba

  • Contact email

    ctregulatoryaffairsukandireland@bms.com

  • Sponsor organisation

    Bristol-Myers Squibb Services Unlimited Company

  • Clinicaltrials.gov Identifier

    NCT07076121

  • Research summary

    This study will assess the safety and effectiveness of BMS-986504 in people with untreated metastatic pancreatic ductal adenocarcinoma (PDAC) who have a specific genetic mutation called homozygous MTAP deletion.
    Homozygous MTAP deletion occurs in approximately 20-25% of patients with PDAC and is associated with shorter survival and acquired resistance to drugs that use the immune system to target cancer.
    There are 2 phases to this study. Phase 2 will test 2 different doses of BMS-986504 (400 mg and 600 mg once a day). Once it has been determined which dosage is the most effective and safest, phase 3 will start.
    120 participants are needed for phase 2 and 350 for phase 3.
    Everyone will get nab-paclitaxel and gemcitabine (standard chemotherapy). On top of the chemotherapy, participants will be randomly assigned to receive the study drug or the placebo.
    Participants are first pre-screened to determine if their cancer has the genetic change (MTAP deletion). Participants that have the genetic change enter a screening period (up to 28-days) where they undergo further assessments to determine their suitability. If suitable, participants enter the treatment period. Study treatment continues until disease progression (worsening of their cancer); intolerable toxicity (unacceptable side effects) or withdrawal of consent. When their treatment ends, participants enter a follow-up period. There will be 1 in-person visit 28 days after the last dose and then check-ins every 2 months for up to 3 years.
    Participants will undergo the following assessments and tests, many of which are non-invasive: medical examinations, vital signs (like blood pressure, heart rate), heart tests like ECGs, blood and urine samples and scans (CT and/or MRI). There will be health related questionnaires to complete.

  • REC name

    London - Harrow Research Ethics Committee

  • REC reference

    25/LO/0580

  • Date of REC Opinion

    30 Sep 2025

  • REC opinion

    Further Information Favourable Opinion